Metoprolol tartrate product
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0581-2025
Blood pressure / heart
Metoprolol tartrate 25 mg
Public data on metoprolol from CMS and FDA: what pharmacies have paid for it, how many generic applications FDA has approved, and whether it appears in FDA's shortage or recall records.
$0.0160
NADAC per ea (2026-11)
approximate acquisition cost, not a retail price
-31%
change over five years
peak $0.0284 in 2014-04
32
approved generic applications (ANDAs) on record for Metoprolol Tartrate
15 with a product still marketed · first 1993
Not listed
in FDA's current shortage list
no matching FDA shortage entries
NADAC per unit, monthly
METOPROLOL TARTRATE 25 MG TABShow as table
| Month | NADAC per unit ($) |
|---|---|
| 2013-11 | 0.02675 |
| 2014-02 | 0.02840 |
| 2014-05 | 0.02522 |
| 2014-08 | 0.02409 |
| 2014-11 | 0.02501 |
| 2015-02 | 0.02705 |
| 2015-05 | 0.02706 |
| 2015-08 | 0.02518 |
| 2015-11 | 0.02508 |
| 2016-02 | 0.02622 |
| 2016-05 | 0.02633 |
| 2016-08 | 0.02686 |
| 2016-11 | 0.02594 |
| 2017-02 | 0.02337 |
| 2017-05 | 0.02335 |
| 2017-08 | 0.02273 |
| 2017-11 | 0.02341 |
| 2018-02 | 0.02346 |
| 2018-05 | 0.02215 |
| 2018-08 | 0.01991 |
| 2018-11 | 0.01830 |
| 2019-02 | 0.01955 |
| 2019-05 | 0.01992 |
| 2019-08 | 0.02565 |
| 2019-11 | 0.02529 |
| 2020-02 | 0.02266 |
| 2020-05 | 0.02267 |
| 2020-08 | 0.02223 |
| 2020-11 | 0.02205 |
| 2021-02 | 0.02482 |
| 2021-05 | 0.02421 |
| 2021-08 | 0.02282 |
| 2021-11 | 0.02325 |
| 2022-02 | 0.01935 |
| 2022-05 | 0.01835 |
| 2022-08 | 0.01797 |
| 2022-11 | 0.01808 |
| 2023-02 | 0.01618 |
| 2023-05 | 0.01666 |
| 2023-08 | 0.01698 |
| 2023-11 | 0.01833 |
| 2024-02 | 0.01792 |
| 2024-05 | 0.01551 |
| 2024-08 | 0.01582 |
| 2024-11 | 0.01591 |
| 2025-02 | 0.01620 |
| 2025-05 | 0.01767 |
| 2025-08 | 0.01765 |
| 2025-11 | 0.01707 |
| 2026-02 | 0.01760 |
| 2026-05 | 0.01715 |
| 2026-08 | 0.01618 |
| 2026-11 | 0.01603 |
Source: CMS NADAC weekly files, generic rows, monthly median of weekly averages · data as of 2026-11. Figures can change and may contain errors in the source data. Check the original source before relying on them.
Recall records mentioning metoprolol
openFDA enforcement records, by year reported.
| 2025 | 2 |
| 2024 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2018 | 2 |
| 2014 | 5 |
| 2012 | 1 |
14 records since 2012. A record is one product or lot, not one recall event. Combination products that contain metoprolol are included.
What these numbers mean
NADAC is what retail pharmacies pay on average to buy the drug, published by CMS. It does not include rebates and is not what you pay at the counter. ANDA counts include all strengths and forms and applications whose products are now discontinued.
Most recent recall records
Metoprolol tartrate product
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0582-2025
Metoprolol tartrate tablets
Reason category: Sterility / contamination
FDA recall number D-0517-2024
Metoprolol tartrate tablets
Reason category: Sterility / contamination
FDA recall number D-0362-2022
Metoprolol tartrate tablets
Reason category: Sterility / contamination
FDA recall number D-0812-2021
Not health advice. GxRadar is for general information only. Nothing here is medical, pharmacy, legal or financial advice. Do not start, stop or change any medicine based on this site. Talk to your pharmacist or prescriber about your own situation.
Related reading
Equivalence & alternatives · Explainer · 5 min
Authorized generics are the brand drug under a generic label
How an authorized generic differs from an ordinary generic, why brand companies launch them during the first filer's 180 days, what the FTC found about prices and settlements, and how to read FDA's list.
The approval pathway · Explainer · 5 min
Bioequivalence and the 80-125 rule
The 80 to 125 percent range is a statistical test on blood levels. It does not let a generic hold 20 percent less drug. How the test works, what FDA's May 2026 guidance says, and what 2,070 studies showed.
Equivalence & alternatives · Explainer · 5 min
Complex generics and why some drugs still have few or no copies
Inhalers, peptide injections, creams and long-acting shots are hard to copy. What FDA counts as complex, how its product-specific guidances and pre-ANDA meetings work, and what recent approvals show.
The approval pathway · Explainer · 5 min
How a generic drug gets approved
Every US generic goes through an Abbreviated New Drug Application. What goes into one, how FDA reviews it, the GDUFA III deadlines, and why a finished review can still end in a tentative approval.
Equivalence & alternatives · Explainer · 5 min
How biosimilars differ from generics
Biosimilars and generics are approved under different laws and sameness tests. How the 351(k) pathway works, what interchangeability means at the pharmacy, and how many biosimilars FDA had approved by October 2026.
Using medicines safely · Explainer · 5 min
How drug expiration dates are set
What the expiration date on a medicine means under federal rules, how stability testing produces it, what the federal Shelf Life Extension Program found, and when FDA has allowed use past labeled dates during shortages.